Free tool
FAERS Monitor: Arimidex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020541 or its brand name (Arimidex, Anastrozole). Reports on generic versions are filed under their own applications.
Reports
37,157
Serious
25,421
68% of reports
Hospitalization
8,122
Death reported
2,478
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue3,541
- arthralgia3,276
- nausea2,844
- alopecia2,620
- diarrhoea2,441
- pain1,887
- headache1,836
- asthenia1,647
- dyspnoea1,620
- dizziness1,571
- pain in extremity1,461
- hot flush1,445
- malignant neoplasm progression1,426
- vomiting1,376
- malaise1,360
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 278 |
| 2005 | 385 |
| 2006 | 549 |
| 2007 | 1,232 |
| 2008 | 1,491 |
| 2009 | 1,838 |
| 2010 | 1,308 |
| 2011 | 1,385 |
| 2012 | 1,449 |
| 2013 | 965 |
| 2014 | 994 |
| 2015 | 1,268 |
| 2016 | 1,609 |
| 2017 | 1,936 |
| 2018 | 2,254 |
| 2019 | 2,548 |
| 2020 | 2,234 |
| 2021 | 2,081 |
| 2022 | 2,315 |
| 2023 | 2,611 |
| 2024 | 2,273 |
| 2025 | 2,267 |
| 2026 | 1,886 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,017,002 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hot flushSignal | 1,445 | 11.0 | 10.5 | 12,985 |
| malignant neoplasm progressionSignal | 1,426 | 8.0 | 7.6 | 8,619 |
| alopeciaSignal | 2,620 | 7.6 | 7.4 | 15,053 |
| arthralgiaSignal | 3,276 | 4.5 | 4.3 | 8,983 |
| pain in extremitySignal | 1,461 | 2.8 | 2.7 | 1,725 |
| fatigueSignal | 3,541 | 2.6 | 2.5 | 3,545 |
| astheniaSignal | 1,647 | 2.5 | 2.4 | 1,482 |
| diarrhoeaSignal | 2,441 | 2.1 | 2.1 | 1,532 |
| nauseaSignal | 2,844 | 2.0 | 2.0 | 1,555 |
| dizziness | 1,571 | 1.8 | 1.7 | 553 |
| malaise | 1,360 | 1.8 | 1.7 | 451 |
| pain | 1,887 | 1.7 | 1.7 | 611 |
| headache | 1,836 | 1.7 | 1.6 | 494 |
| vomiting | 1,376 | 1.7 | 1.6 | 366 |
| dyspnoea | 1,620 | 1.6 | 1.5 | 395 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.